Cell and gene therapies are advancing into late-stage development and commercialization, where raw materials have become a critical determinant of whether programs succeed or fail. Small inconsistencies that once went unnoticed are now triggering regulatory scrutiny, inflating cost of goods, and causing delays that put timelines and patient access at risk. Following the sunshine to […]

After a decade of innovation, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already, the headwinds are reversing with $15B worth of upfront […]

The 14th IMPACCT Real-World Evidence Summit is the only dedicated industry forum uniting leaders across RWE, real-world data, evidence generation, HEOR, and market access to tackle the most pressing challenges in the field. From selecting regulatory-ready datasets to embedding AI and advanced analytics into workflows, this summit focuses on how to consistently translate data into […]

GLP-1s changed the treatment paradigm for obesity reaching new heights of efficacy. Now, as unmet need persists and the field looks beyond efficacy alone, momentum is building behind therapies that can deliver lasting weight management through improved tolerability, muscle preservation, personalised treatment approaches, and more convenient administration. As obesity investment and pipeline activity surge across […]

The 9th RNA-Targeted Drug Discovery & Development Summit returns to Boston, MA, on November 10–12, 2026, as the industry's only dedicated meeting focused exclusively on RNA-targeted small molecules, bringing together leading minds from biotech, pharma and academia to advance the next generation of RNA-focused therapeutics. As momentum continues to build across the field, driven by recent clinical progress and […]

The 9th Lab Asset & Facility Management (LAFM) Summit 2026 is the leading industry forum dedicated to helping pharmaceutical and biotech organizations optimize lab operations, asset management, facilities, engineering, and research infrastructure. Taking place in Boston, MA from November 10–12, 2026, the flagship event brings together 190+ senior leaders and decision-makers responsible for creating efficient, […]

South Korea’s cell and gene therapy landscape is highly dynamic, as observed from regulatory approvals, clinical trial progress, and manufacturing activity, from over 150 companies in active drug development. Additionally, with global pharma including Bayer, Novartis and more seeing strategic investments into the CGT space within South Korea, greater opportunities for scientific innovation and technology […]

Driven by South Korea’s government making strategic investments in mRNA platforms and growing collaboration between global pharma and local biotech innovators, the field is experiencing renewed development momentum. This is placing the region as a key hotspot for global mRNA innovation and interest. Uniquely positioned as the industry’s most comprehensive biopharma forum, the 2nd World RNA-Based Therapeutic […]

Hot off the press: The biomarker operations and biospecimen community finally has its own dedicated forum. Introducing the inaugural Biomarker Operations & Biospecimen Management Summit, the industry's first, purpose-built meeting for the heads, VPs and leading stakeholders at pharma and biotech directly responsible for biospecimen and biomarker delivery. View the newly released agenda:  https://ter.li/p9sor70u With […]

As model-informed drug development (MIDD) becomes increasingly central to modern drug development strategy, organizations are under growing pressure to leverage quantitative approaches that accelerate timelines, reduce risk, and improve regulatory and clinical success. The 2nd Model-Informed Drug Development Summit, taking place November 17-19, 2026, in Boston, MA, brings together senior leaders in pharmacometrics, clinical pharmacology, […]

Introducing Europe’s first CNS Biomarker Forum. The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid, imaging, and digital biomarkers for CNS drug development. Bringing together biomarker, translational medicine, neuroscience, and clinical development leaders, the summit focuses on accelerating the discovery, validation, and implementation of next-generation biomarkers across neurodegenerative and […]

The 8th CNS Drug Delivery Summit is the leading industry forum dedicated to overcoming the challenges of delivering therapeutics across the blood-brain barrier and into the central nervous system. Bringing together experts from biopharma, biotech, and academia, the summit will explore the latest advances in drug delivery technologies, including nanoparticles, antibody shuttles, gene therapy vectors, […]